Soarin' Eagle

Microba Life Sciences and Ginkgo Bioworks Announce Partnership to Discover Novel Live Biotherapeutics

Retrieved on: 
Monday, April 4, 2022
Health, Genetics, Other Health, Research, Science, Pharmaceutical, Biotechnology, Risk, Soarin' Eagle, Form 10-K, Therapy, Conditional sentence, Degenerative disease, DNA, Fermentation, Forward-looking statement, Synthetic biology, Canaccord Genuity, K-12, China Biologic Products, Bell Potter, NYSE, Annual report, Bacteria, LBP, SEC, Biotechnology, Program, Decision-making, CEO, Health, MAP, Senior, Agriculture, ASX, Australian Securities Exchange, Lupus, U.S. Securities and Exchange Commission, COVID-19, Computer, List of life sciences, IPO, Food, Disease, Partnership, Dietary supplement, Antibiotics, Ginkgo, MICROBA LIFE SCIENCES, GINKGO BIOWORKS

Microba Life Sciences (ASX: MAP), a precision microbiome science company, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a partnership to identify single-strain, live bacteria product (LBP) candidates against autoimmune diseases.

Key Points: 
  • Microba Life Sciences (ASX: MAP), a precision microbiome science company, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a partnership to identify single-strain, live bacteria product (LBP) candidates against autoimmune diseases.
  • Microba Life Sciences plans to launch its Initial Public Offering (IPO) on the Australian Securities Exchange (ASX) on April 5.
  • In connection with the partnership, Ginkgo is investing $3.5 million USD in Microba.
  • Microba Life Sciences is a precision microbiome company driving the discovery and development of novel therapeutics for major chronic diseases to improve human health.

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Monday, March 28, 2022
Well, Total, Risk, Earnout, RSU, Soarin' Eagle, Food, Therapy, Sale, DNA, Beacon, Forward-looking statement, Synthetic biology, Climate change, K-12, Growth, NYSE, GAAP, Foundry, Biotechnology, SEC, Investor relations, Program, CEO, Agriculture, Concentric objects, COVID-19 testing, Industry, Technology, Biology, Cell, Twitter, U.S. Securities and Exchange Commission, COVID-19, Computer, Adjustment, Nature, Food security, Animal, Renewable energy, Semiconductor, Pharmaceutical industry, Video game, Bank, Beauty salon, Risk management, Ginkgo, Biosecurity

BOSTON, March 28, 2022 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), the leading horizontal platform for cell programming, today announced its results for the fourth quarter and year ended December 31, 2021. The update, including a webcast slide presentation with additional details on the fourth quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

Key Points: 
  • The update, including a webcast slide presentation with additional details on the fourth quarter and supplemental financial information, will be available at investors.ginkgobioworks.com .
  • Fourth quarter 2021 Total revenue of $148 million, up from $32 million in the comparable prior year period, an increase of 363%.
  • Fourth quarter 2021 Foundry revenue of $34 million, up from $16 million in the comparable prior year period, an increase of 108%.
  • Fourth quarter 2021 Adjusted EBITDA of $1 million, improved from $(51) million in the comparable prior year period.

Phytolon and Ginkgo Bioworks Collaborate to Take Biological Production of Vibrant Food Colors to the Next Level

Retrieved on: 
Monday, February 28, 2022
Consensus, Commercial, Risk, U.S. Securities and Exchange Commission, Therapy, Partnership, SGX, Efficiency, CTO, Cell engineering, Computer, Biotechnology, K-12, COVID-19, Industry, Fermentation, Biology, Food industry, NYSE, DNA, Soarin' Eagle, Food, Forward-looking statement, Synthetic biology, Ginkgo Bioworks, Technology, Agriculture, Solution, Program, SEC, Cochineal, Fine chemical, Ginkgo

YOKNEAM ILLIT, Israel, Feb. 28, 2022 /PRNewswire/ -- Phytolon, a growing startup company making natural food colorants, announced a partnership today with Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, to produce vibrant cultured food colors via fermentation of yeast. Under this partnership, Phytolon is leveraging Ginkgo's ability to engineer biology at scale to work together on the production of vibrant betalain pigments, the healthy and colorful compounds found in foods like beets and cactus fruit. The project aims to take Phytolon's colors across the full 'yellow-to-purple' spectrum to the next level, and to potentially maximize the business opportunity of Phytolon's vibrant colors for applications in the food and cosmetics industries.

Key Points: 
  • The project aims to take Phytolon's colors across the full 'yellow-to-purple' spectrum to the next level, and to potentially maximize the business opportunity of Phytolon's vibrant colors for applications in the food and cosmetics industries.
  • Biotechnology offers an opportunity to tap into the vibrant colors of biology to produce more sustainable, yet equally vibrant, colors.
  • While artificial dyes are visually appealing and cheap to manufacture, many have been banned in food and feed due to health concerns.
  • Together, Phytolon and Ginkgo are partnering with the goal of maximizing the production efficiency of purple and yellow betalain-producing strains.

New Commercial BVLOS Milestone - Longest Distance Allowed by FAA at 12 Miles

Retrieved on: 
Wednesday, February 9, 2022
MA, Policy, GLOBE, Federal Aviation Administration, Automation, Agriculture, Risk management, Iapetus, UAV, DAA, Soarin' Eagle, Technology, Safety, Atlas, Unmanned aerial vehicle, Capite censi, MS, Organization, UAS, Aircraft, Transport Canada, Aviation, FAA, Eagle, Acquisition, Airline, Car rental, Iris

The waiver covers a 12-mile distance - the longest distance ever approved by the FAA.

Key Points: 
  • The waiver covers a 12-mile distance - the longest distance ever approved by the FAA.
  • The continued expansion of BVLOS operations means data acquisition with significantly lower cost and environmental impact."
  • "When we submit a waiver now, we have proof from our flight teams, DAA supplier and customers that proves BVLOS mission reliability."
  • The FAA requires drone pilots to maintain visual line of sight at all times with any drone they are operating, unless they have secured a BVLOS waiver.

Ginkgo Bioworks Provides Preliminary Unaudited 2021 Revenue Highlights and Business Review

Retrieved on: 
Wednesday, January 12, 2022
CDC, U.S. Securities and Exchange Commission, Forward-looking statement, Synthetic biology, Conference, Concentric objects, Biotechnology, SEC, COVID-19, NYSE, Travel, Growth, Risk, DNA, Public health, School, Computer, Program, Food, Agriculture, Therapy, Met, Soarin' Eagle, Mission statement, K-12, Investment, Medical device, Pharmaceutical industry, Risk management, Ginkgo, Biosecurity

BOSTON, Jan. 12, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today preliminary performance updatesfor the year ended December 31, 2021.

Key Points: 
  • BOSTON, Jan. 12, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today preliminary performance updatesfor the year ended December 31, 2021.
  • The results, along with a broader business review, will be featured in a presentation today at the 40th Annual J.P. Morgan Healthcare Conference.
  • Met goal to add at least 30 new programs in 2021, resulting in over 100 cumulative cell programs being launched at Ginkgo.
  • Preliminary unaudited Foundry revenue is expected to exceed previously disclosed outlook of $100 million for full year 2021, inclusive of both downstream value share and services revenue.

Selecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-Generation Gene Therapy Capsids

Retrieved on: 
Monday, January 10, 2022
SEC, Safety, Risk, DNA, Intention, Synthetic biology, Security (finance), Computer, Soarin' Eagle, U.S. Securities and Exchange Commission, Forward-looking statement, Annual report, Agriculture, Program, Partnership, Â, CEO, Private Securities Litigation Reform Act, NYSE, Company, Nasdaq, AAV, Cell engineering, Degenerative disease, Intellectual property, COVID-19, Therapy, Tropism, GLOBE, Food, K-12, Biotechnology, Vaccine, Risk management, Selecta, Greater Boston, Ginkgo

Ginkgo plans to design and engineer the capsids and Selecta will conduct all pre-clinical and clinical studies thereafter.

Key Points: 
  • Ginkgo plans to design and engineer the capsids and Selecta will conduct all pre-clinical and clinical studies thereafter.
  • By combining ImmTOR with next-generation, fit-for-purpose AAV vectors, we hope to further improve the safety and efficacy of AAV-mediated gene therapies.
  • Jason Kelly, CEO of Ginkgo Bioworks, added, Gene therapies utilize naturally occurring viral capsids that elicit immune responses and often exhibit safety and toxicity issues.
  • We believe our collaboration with Selecta has the potential to confront major challenges within the gene therapy space and represents an important application of our cell programming platform.

Optimvia and Ginkgo Bioworks Announce Partnership to Manufacture Biosynthetic Heparin

Retrieved on: 
Thursday, January 6, 2022
Ecosystem, Engineering, COVID-19, Agriculture, Program, Heparin, Enzyme, World Health Organization, Therapy, Forward-looking statement, NYSE, DNA, Extrapyramidal system, ADEPT, K-12, U.S. Securities and Exchange Commission, Risk, Efficiency, CEO, Soarin' Eagle, SEC, Partnership, Livestock, World, Technology, Computer, Synthetic biology, Insulin, Food, Biotechnology, Fine chemical, Pharmaceutical industry, Genentech, Ginkgo

Under the partnership, Optimvia seeks to leverage Ginkgo's cell and enzyme engineering platform, as well as its fermentation process development expertise, to rapidly improve the performance of Optimvia's biosynthetic heparin manufacturing technology.

Key Points: 
  • Under the partnership, Optimvia seeks to leverage Ginkgo's cell and enzyme engineering platform, as well as its fermentation process development expertise, to rapidly improve the performance of Optimvia's biosynthetic heparin manufacturing technology.
  • "The goal of producing biosynthetic heparin is similar to Genentech's famous breakthrough of creating insulin through recombinant cell-based methods as opposed to relying on extraction from pig pancreas," said Keith Kleeman, CEO, Optimvia.
  • "Ginkgo's platform helps emerging startups develop and optimize their products and reach commercial scale," said Jason Kelly, CEO, Ginkgo Bioworks.
  • Biosynthetic heparin is the first commercial candidate Optimvia has developed using its ADEPT platform.

Benjamin Franklin Institute of Technology, Ginkgo Bioworks to Launch Biotechnology Manufacturing Associates Degree

Retrieved on: 
Monday, December 20, 2021
Organization, Forward-looking statement, U.S. Securities and Exchange Commission, Workforce, Computer, Madison Park Technical Vocational High School, Agriculture, Annissa Essaibi George, Electrical engineering, List of life sciences, Program, NYSE, National Park Service training centers, Nubian Square, COVID-19, Benjamin Franklin Institute of Technology, HVAC, SEC, Bachelor of Engineering, Risk, CEO, Biotechnology, HVAC&R, Therapy, DNA, K-12, Synthetic biology, Maintenance, Roxbury Community College, Student, Food, Partnership, Soarin' Eagle, Medicine, Management, Technology, Automotive industry, Science, Ginkgo, Mathematics

BOSTON, Dec. 20, 2021 /PRNewswire/ --Benjamin Franklin Institute of Technology (BFIT), a private non-profit college offering affordable education for people seeking technical and trade careers, announced today a partnership with Ginkgo Bioworks (NYSE: DNA) to develop an associate degree in biotechnology manufacturing.

Key Points: 
  • BOSTON, Dec. 20, 2021 /PRNewswire/ --Benjamin Franklin Institute of Technology (BFIT), a private non-profit college offering affordable education for people seeking technical and trade careers, announced today a partnership with Ginkgo Bioworks (NYSE: DNA) to develop an associate degree in biotechnology manufacturing.
  • The report also found that at the associate degree and high school graduate levels, job demand has grown by 140%.
  • "This new associate's degree in biotechnology manufacturing positions our students to play a critical role in supplying a diverse and qualified workforce to fill Massachusetts' booming life science and medical industry."
  • It's time for that misconception to be corrected," said Reshma Shetty, co-founder, Chief Operating Officer and President of Ginkgo Bioworks.

Eurofins’ Clinical Enterprise Launches New Partnership with Ginkgo Bioworks to Support Federally Funded COVID-19 PCR Testing Program

Retrieved on: 
Monday, December 13, 2021
Primary, Secondary, Preschool, Education, Health, General Health, University, Organization, Forward-looking statement, U.S. Securities and Exchange Commission, Computer, Agriculture, Concentric objects, Genomics, COVID-19 testing, Prison, Life, NYSE, Public health, Environment, COVID-19, SEC, Risk, Biotechnology, Federal government of the United States, Enterprise, Therapy, Department, DNA, K-12, Government, Laboratory, U.S. Department of Defense Strategy for Operating in Cyberspace, Synthetic biology, Program, Airport, School, Pharmacology, Human services, Partnership, Food, Soarin' Eagle, Black Ivy League, Pharmaceutical industry, Eurofins Scientific, Ginkgo, Eurofins – the global leader in bio-analysis, Ginkgo, EUROFINS – THE GLOBAL LEADER IN BIO-ANALYSIS, GINKGO

Clinical Enterprise, Inc., a Eurofins Scientific Company, today announced it has launched a new partnership with Ginkgo Bioworks (NYSE: DNA) to support Operation Expanded Testing Program with the U.S. Department of Health and Human Services and Department of Defense.

Key Points: 
  • Clinical Enterprise, Inc., a Eurofins Scientific Company, today announced it has launched a new partnership with Ginkgo Bioworks (NYSE: DNA) to support Operation Expanded Testing Program with the U.S. Department of Health and Human Services and Department of Defense.
  • Operation Expanded Testing provides fully federally funded COVID-19 PCR testing to K-12 public and private schools, Historically Black Colleges & Universities, daycare centers, community organizations, congregate settings, correctional facilities, and underserved communities.
  • The program helps to equip these organizations with testing guidance and resources, promoting equity in COVID-19 testing and mitigation.
  • Throughout the pandemic, Ginkgo Bioworks has supported widespread surveillance testing through its biosecurity and public health effort, Concentric by Ginkgo.

XpresSpa Group and Ginkgo Bioworks Collaboration with the Centers for Disease Control and Prevention (CDC) COVID-19 Biosurveillance Program Expands to Include Detection of the New Omicron Variant

Retrieved on: 
Tuesday, November 30, 2021
World Health Organization, Sumathi Best Television Current Reporting Award, Risk, Annual report, Company, NYSE, White, Weather, Korea Disease Control and Prevention Agency, Concentric objects, K-12, DNA, GLOBE, Biotechnology, Global health, World, Division, Travel, Securities Exchange Act of 1934, U.S. Securities and Exchange Commission, Computer, Public health, Food, Hartsfield–Jackson Atlanta International Airport, San Francisco International Airport, Forward-looking statement, Partnership, Health, Therapy, White House, Agriculture, Omicron, Map, Terminology, Center, Airport, Securities Act of 1933, Soarin' Eagle, Technology, PCR, Severe acute respiratory syndrome coronavirus 2, Synthetic biology, SEC, Newark Liberty International Airport, Program, COVID-19, Nasdaq, CDC, Animal, Airline, Tourism, Security (finance), Risk management

Information about the Omicron variant is rapidly evolving, said Dr. Martin Cetron, the Director for the Division of Global Migration and Quarantine (DGMQ) at the U.S. Centers for Disease Control and Prevention (CDC).

Key Points: 
  • Information about the Omicron variant is rapidly evolving, said Dr. Martin Cetron, the Director for the Division of Global Migration and Quarantine (DGMQ) at the U.S. Centers for Disease Control and Prevention (CDC).
  • We are actively working to scale up this collaborative post-arrival airport-based surveillance testing program to monitor for this new variant in arriving travelers.
  • The CDCs program, conducted in collaboration with XpresCheck and Ginkgo Bioworks, offers two types of free testing options.
  • XpresSpa Group, Inc.(Nasdaq: XSPA) is a leading global health and wellness holding company operating three distinct brands: Treat, XpresCheck, and XpresSpa.